Defender Capital LLC. Lowers Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Defender Capital LLC. lessened its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 7.9% in the fourth quarter, Holdings Channel reports. The firm owned 39,085 shares of the biotechnology company’s stock after selling 3,374 shares during the quarter. Axon Enterprise accounts for about 8.5% of Defender Capital LLC.’s investment portfolio, making the stock its 5th largest position. Defender Capital LLC.’s holdings in Axon Enterprise were worth $23,229,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its position in Axon Enterprise by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after purchasing an additional 35,320 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after buying an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC increased its holdings in Axon Enterprise by 13.9% during the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after buying an additional 83,265 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Axon Enterprise by 1.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock worth $224,281,000 after acquiring an additional 9,090 shares during the period. Finally, Groupama Asset Managment purchased a new stake in shares of Axon Enterprise during the third quarter worth $200,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Robert W. Baird upped their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. JMP Securities lifted their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a report on Thursday, October 31st. Needham & Company LLC upped their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, The Goldman Sachs Group increased their price objective on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research report on Monday. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $524.85.

Axon Enterprise Stock Performance

Shares of AXON opened at $639.97 on Thursday. The stock has a market capitalization of $48.80 billion, a P/E ratio of 165.37, a P/E/G ratio of 6.09 and a beta of 1.04. The company’s fifty day moving average is $618.90 and its two-hundred day moving average is $477.78. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a 1 year low of $247.04 and a 1 year high of $698.67.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $606.15, for a total value of $12,123,000.00. Following the completion of the sale, the president now directly owns 208,166 shares in the company, valued at approximately $126,179,820.90. The trade was a 8.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the transaction, the director now directly owns 6,929 shares in the company, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,545 shares of company stock worth $30,721,337 over the last 90 days. Company insiders own 6.10% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.